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Edited by Horst FeldmannAbstract The linkage between internal ribosomal symmetry
and transfer RNA (tRNA) positioning conﬁrmed positional
catalysis of amino-acid polymerization. Peptide bonds are
formed concurrently with tRNA-30end rotatory motion, in
conjunction with the overall messenger RNA (mRNA)/tRNA
translocation. Accurate substrate alignment, mandatory for the
processivity of protein biosynthesis, is governed by remote
interactions. Inherent ﬂexibility of a conserved nucleotide,
anchoring the rotatory motion, facilitates chirality discrimina-
tion and antibiotics synergism. Potential tRNA interactions
explain the universality of the tRNA CCA-end and P-site
preference of initial tRNA. The interactions of protein L2 tail
with the symmetry-related region periphery explain its conser-
vation and its contributions to nascent chain elongation.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Ribosomes are the cellular organelles catalyzing polymeri-
zation of amino acids according to the genetic code sequence,
encoded in messenger RNA (mRNA). Transfer RNA (tRNA)
molecules carry the amino acids, esteriﬁed to their 30ends,
which consists of the universally conserved single-stranded
sequence CCA. Ribosomes possess three tRNA binding sites,
A, P and E, hosting the aminoacyl, peptidyl-tRNA and the
exiting tRNA, respectively. Each elongation cycle involves the
advancement of the mRNA together with A!P!E-site
passage of the tRNA molecules, driven by GTPase activity.
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functionally active ribosome, the small subunit interacts with
the tRNA anticodon triplet and the large subunit provides the
peptidyl transferase center (PTC) center and the path for the
nascent protein, hence interacting with the tRNA acceptor
stem and its CCA end. Analysis of the available ribosomal
structures of eubacteria [1–4] and archaea [5] showed that both
the decoding site and the PTC consist exclusively of ribosomal
RNA (rRNA). Being the main player in a fundamental cell
process, the ribosome is targeted by many clinically relevant
antibiotics. These were shown to hamper protein biosynthesis
by limiting ribosomal mobility, by blocking the progression of
nascent proteins or by perturbing the architecture of the
ribosomal active centers.
Here, we discuss the linkage between the spectacular ribo-
somal architecture, its crucial conformational mobility and
antibiotics synergism. We also address positional catalysis of
peptide-bond formation and nascent chain elongation, chiral-
ity discrimination, the universality of the tRNA CCA end and
the possible contribution of a ribosomal protein to partial
stabilization of the dynamic PTC.2. Positional catalysis
The PTC is located in the large subunit, close to the subunit
interface, at the bottom of a cavity (Fig. 1(a)) that opens into a
long tunnel that spans the large subunit and serves as the path
taken by nascent peptides until they emerge out of the ribo-
some. The PTC crevice and its environment are located in the
midst of a sizable symmetry-related region, containing about
180 nucleotides, revealed by us in all known structures of the
large ribosomal subunit (Fig. 1(b)) [3–15]. This unique sym-
metrical region within the otherwise asymmetrical ribosome
relates the RNA backbone fold and the nucleotides orienta-
tions, rather than their types. It encapsulates the PTC, and its
symmetry axis that passes midway between the A and the P
loops, almost coincides with the long axis of the protein exit
tunnel [11,16–18]. The requirement to oﬀer comparable sup-
portive environments to two similar chemical moieties in anation of European Biochemical Societies.
Fig. 1. (a) The D50S PTC cavity viewed from the subunit interface,
together with ASM, a 35 nucleotides substrate analog mimicking the
A-site tRNA acceptor stem and its aminoacylated 30end [11]. The
nucleotides known to form basepairs with tRNAmolecules are marked
by their numbers. (b) Two perpendicular views of the RNA backbone
of the symmetry related region in all known structures [3–5]. The
symmetry axis is red. The bottom view shows also the ASM 30end (at
the A-site, in blue) and the derived P-site 30end (in green), both shown
as atoms. (c) The position of the symmetry related region within the
large subunit. Its connections with the tRNA entrance and exit re-
gions, as well as with the decoding site in the small subunit, are colored
(in purple). Also shown are the docked three tRNA molecules, bound
to the whole ribosome [3], as well as the 30ends of ASM and the derived
P-site tRNA. In all, the rRNA backbone is shown as gray ribbons. Top
panel: The front (left) and side (right) views of D50S. Bottom left in-
cludes the small subunit, as determined within the entire ribosomes [3].
Bottom right shows the colored features in all other views, including
the symmetry related region, its axis, Helix H69 and the docked tRNA
molecules. Note the strategic location of H69, consistent with its major
contribution to the accurate placement of A-site tRNA, and to its
presumed function in translocation [16,17,31].
Fig. 2. (a) A translocating tRNA, from A-(blue) to P-(green) site. The
dark green line shows the division between the double helical region
that is being shifted (above the line) and the rotating 30end (below),
based on ASM position within D50S. As ASM [11] binds only to the
large subunit, the tRNA regions that interact with the small subunit
are represented by hollow blue-green boxes. The straight arrows show
the shifting direction, and the round one represents the rotatory mo-
tion. (b–d) The PTC boundaries scaﬀolding the path of the rotatory
motion. The positions of A2602 and U2585 are marked. (b) The right
panel of (c) and (d) show views down the symmetry axis, from the
tunnel towards the PTC. The right side of (c) is a view along the
symmetry axis. In (b) the rotatory motion is represented by the gradual
transfer from blue (A) to green (P) site. The ﬁgure shows snapshots of
the rotatory motion, obtained by successive rotations from A-to P-site
of the rotating moiety by 15 each, around the bond connecting the
30end with the rest of the tRNA molecule. (d) Shows the position of the
adenylated A76 of the tRNA at the A-site (as in ASM) and its derived
P-site. The atoms involved in the actual peptide bond process are
highlighted on the right. (e) A superposition of several substrate ana-
logs, as observed in H50S [19] and D50S [11]. Note the similarity in the
positions and the diﬀerences in the orientations.
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internal symmetry [18]. This symmetry-related region connects,
directly or through its extensions, all functional regions of
the large subunit, namely the tRNA entrance and exit sites, the
PTC, the protein exit tunnel, with the decoding center in the
small subunit (via the intersubunit bridge B2a, which is the tip
of Helix H69) (Fig. 1(c)). Its central location suggests that it
provides an intra-ribosomal functional signaling system be-
tween remote functional locations, essential for smooth pro-
cessivity of amino-acids polymerization.We found that for substrates that are positioned accurately,
the bond connecting the aminoacylated tRNA-30end to the rest
of the tRNA molecule coincides with the symmetry axis of the
symmetry-related region. Thus, it appears that tRNA trans-
location consists of two correlated movements: a rotation of
the tRNA single-stranded terminus and a shift of the tRNA
helical regions combined with the mRNA progression at the
decoding site (Fig. 2(a)) [11,17]. An additional mechanistic
element of the rotatory motion is its spiral nature. Thus, four
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compared to their A-site mates appear to guide the nascent
chain into the exit tunnel [11,17].
The PTC is an arched void of an architecture speciﬁcally de-
signed for theA- to P-site rotatorymotion, as its dimensions and
shape are suitable to accommodate tRNA-30ends throughout
this passage and its boundaries create the template along which
the rotating moiety slides (Fig. 2(b)) [11]. Two conserved nu-
cleotides, A2602 (Escherichia coli numbering system is used
throughout) and U2585 bulging from the PTC wall into its
center, appear to provide a double-anchor for this motion (Figs.
2(b)–(d)) [11]. Guided by the rRNA scaﬀold along an exact
pattern, the rotatory motion leads to stereochemistry optimal
for peptide-bond formation (Fig. 2(d)), which seems to occur
concurrently with the rotatory motion. This stereochemistry
allows an A-site primary amine nucleophilic attack on the P-site
tRNA carbonyl-carbon. This reaction should readily take place
at the pH found to be optimal for protein biosynthesis (7.5),
which is close to the pH within D50S-complex crystals, the
system exploited for the determination of the peptide-bond
formation mechanism [11].
It seems, therefore, that the primary catalytic activity of the
ribosome is the provision of an ingeniously designed structural
framework, capable of guaranteeing smooth amino-acid po-
lymerization. Composed of the structural components crucial
for accurate tRNA substrates alignment, translocation along a
guided template, and the entrance of the polypeptide into the
exit tunnel, this framework is located in a central ribosomal
region, interacting with all its functional domains, and appears
to facilitate transfer of information between them. Hence, we
concluded that the ribosome performs its dual catalytic tasks:
peptide-bond formation and amino-acid polymerization by
positioning catalysis [20,21], rather than by participating in
actual chemical events, as suggested previously based on the
crystal structure of a complex of H50S and a compound sup-
posed to mimic an intermediate state analog [6,19].
The geometrical requirement for the ribosomal positional
catalysis, apart from correctly positioned A-site tRNAs, is that
the initial 30end of the P-site tRNA adopts the ﬂipped orien-
tation. Some directionality for P-site positioning could be
provided by the initial amino acid, consistent with its univer-
sality (f-met in prokaryotes or methionine in eukaryotes).
Additionally, the tRNA anticodon loop in the initiation
complex is bound to the P-site of the small subunit. Never-
theless, theoretically the ﬂexible tRNA-30end could be ac-
commodated in various orientations at any position in the
PTC, since at the beginning of protein synthesis both A and P
sites are available. It appears that in order to prevent false
binding, hence avoiding time consuming rearrangements, the
P-site PTC possesses an extra potential candidate for base-
pairing, namely G2252 that can pair with tRNA-C74 [22], in
addition to the symmetrical basepair with tRNA-C75
(Fig. 1(a)). The signiﬁcance of this P-region double basepair
combination, together with the preference of tRNA syntheta-
ses for aminoacyladenylates [23], rationalize the universality of
the CCA motif in tRNA-30end.
Additional deviations from the twofold symmetry at the PTC
are associated with its dynamics. Owing to its tasks, the A-re-
gion possesses more mobility than the rather passive
P-site. The larger number of the intra-region interactions within
the P-region [18], together with the interactions of the outer
region of the P-region with the tail of protein L2 [18], could beresponsible for this unbalanced stabilization. The necessity of
protein L2 for the elongation of nascent polypeptides [24],
contrary to the ability of protein-free 23S rRNA to form single
peptide bonds [25], is consistent with the diﬀerence between
these two stages of protein biosynthesis. Thus, single peptide
bonds can be formed even by approximately placed reactants,
as observed in the crystal structure of a complex of the large
ribosomal subunit from Haloarcula marismortui, H50S [8,19],
whereas the rotatory motion that leads to elongation can be
performed only within a well-outlined pattern, hence necessi-
tating an exact placement in a stable framework.3. Accurate substrate placement within a mobile PTC
A striking net of interactions between the tRNA acceptor
stem and the PTC cavity upper rims (Fig. 1(a)) was observed in
a complex of Thermus thermophilus ribosome, T70S, [3] and of
unbound large subunit from Deinococcus radiodurans, D50S,
with tRNA acceptor stem mimics [11]. In contrast to the dense
network of substrate interactions with the upper rim of the
PTC cavity, only a few contacts were detected within the PTC
itself. Among these is the [26] Watson-Crick basepair between
the A-region G2553 with tRNA C75, which was detected in all
known structures of functional complexes [6,8,10,11]. This
particular basepair was found to be created by tRNA mimics
that bind to the PTC in a similar position, albeit having dis-
tinctly diﬀerent orientations (Fig. 2(e)), all requiring confor-
mational rearrangements for participating in peptide-bond
formation [19]. Inaccurate binding may occur for puromycin
derivatives that are too short to reach the upper rims of the
PTC cavity; or when key constituents of the upper rims, re-
sponsible for the remote interactions (e.g., the tip of H69) are
disordered, as is the case of crystal structure of H50S [5,6]. It
seems, therefore, that the global localization of the tRNA
molecules is dictated by the match between the overall ribo-
somal architecture and the size and shape of the tRNA mol-
ecules; that the universal basepair provides approximate
anchoring even to short substrates, and that the precise sub-
strate alignment is dominated by the remote interactions of the
tRNA double helical acceptor stem with the distant rims of the
PTC [20,21].
The diversity of binding modes observed within the PTC
(summarized in [19–21]) demonstrates the relative ease of ac-
commodating compounds resembling tRNA-30end within the
PTC, and of the formation of single peptide bonds by sub-
strate analogs positioned in diﬀerent orientations [8,19] man-
ifests the PTC mobility. Inherent PTC conformational
tolerance is required for its participation in the dynamic events
associated with peptide-bond formation, and PTC conforma-
tional variability could be correlated to the functional state of
the ribosome, which is, in turn, linked to environmental vari-
ations [27–30]. Similarly, the various PTC conformations ob-
served in the various crystal structures [3,4,6] could be linked
to the functional activity of the crystallized particles, hence to
the relation between physiological and crystallization condi-
tions [4,31].
Comparisons of known PTC conformations [3–15] indicated
possible exploitation of the PTC ﬂexibility for repositioning of
less well-placed substrates [20,21]. A prominent candidate for
this purpose is A2602, the universal nucleotide proposed to
propel the rotatory motion of the tRNA-30end in concert with
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of helix H69 [16,20,21,31] (Fig. 1(c)). A2602 is located at the
center of the PTC close to the symmetry axis (Fig. 2(c)) and
was shown to adopt various orientations [11,16,17]. Beneﬁting
from its mobility, A2602 can assist the post-binding reorien-
tation of approximately bound substrate analogs, a process
bound to consume time, consistent with the lower rate of
peptide-bonds formation by short puromycin derivatives,
called the ‘‘fragment reaction’’, compared to normal protein
biosynthesis [19]. Accordingly, our analysis revealed that ad-
ditional structural requirements have to be fulﬁlled for sub-
jecting the product of the reactions to chain elongation,
consistent with the detection of a dipeptide, formed within
H50S crystals, in the A-site of the PTC [8,19]. These obser-
vations demonstrate that remote interactions dominate pro-
ductive substrate positioning and that accurate substrate
alignment, mandatory for eﬃcient peptide-bond formation
and chain elongation, is achieved by the remote interactions
despite the PTC ﬂexibility.Fig. 3. (a) A presumed D-amino acids position. The ﬁgure provides the
structural basis for the elimination of D-amino acid incorporation. It
shows the results of an attempt to model D-phenylalanine within the
PTC, by overlapping a D-isomer on the ASM 30end, and highlights the
possible contacts of the D-aminoacid model with U2585. (b) A section
through the large ribosomal subunit (in yellow-gray), at the height of
the ribosomal tunnel. P-site tRNA was docked based on its position
within the entire ribosome [3] and the nascent chain has been modeled
as in [12]. The approximate positions of the PTC and of the site tar-
geted by macrolides antibiotics are highlighted in violet and orange,
respectively. (c) The conformational alteration of U2585 induced by
binding of dalfopristin, the SA component of Synercid
, viewed from
the tunnel into the PTC (similar to Fig. 2(b)). The positions of U2585
in the native (U2585n) and the complex with the antibiotics dalfopri-
stin (D) ﬂipped (U2585f) orientation are marked. (d) Two orthogonal
views of the PTC and the tunnel entrance showing the structural basis
for the Synercid synergetic eﬀect. Dalfopristin (D) and Quinupristin
(Q) are colored by cyan and light-green, respectively, and the ap-
proximate volume occupied by them is shaded. Note the edge-on view
of Dalfopristin in the upper panel. Top: a view similar to that shown in
Fig. 2(d), but seen from the opposite side. Bottom: a view approxi-
mately parallel to the symmetry axis, showing also a simulation of the
rotation (performed as for Fig. 2(b)) of A-site tRNA-30end aminoa-
cylated by alanine. (e) The positions of the two molecules of azithro-
mycin (called AZI-1 and AZI-2) bound simultaneously to the ribosome
tunnel. The backbone of the rRNA is shown as yellow ribbons.4. U2585 is involved in anchoring the rotatory motion, in D-
isomer elimination and in antibiotics synergism
Despite the PTC ﬂexibility and its tolerance to non-pro-
ductive substrate placements, it does not allow deviation from
the chirality of its product, the protein. Normally, the tRNA
molecules carry L-amino acids, thus dictating the L-conﬁgu-
ration of the nascent proteins. However, the existence of
minute amounts of D-amino acids could lead to mistakes. The
exclusiveness of L-amino acids in proteins suggests the exis-
tence of ribosomal mechanism for avoiding D-isomer incor-
poration. Modeling attempts revealed two possible
mechanisms: D-isomers rejection by spatial limitations, and the
possibility to lock U2585 in a non-productive conformation
(Fig. 3(a)) [32]. These results are consistent with the suggestion
that D-amino acid incorporation can occur only under sub-
stantial conformational rearrangements [33] that may bypass
both mechanisms.
U2585 is the nucleotide anchoring the rotatory motion
[11,16,17] by direct interaction with the amino acid bound to
the CCA. This universally conserved nucleotide plays a major
role in protein biosynthesis, consistent with the dominant le-
thal phenotypes produced by its mutations [18]. Besides an-
choring the rotatory motion and guaranteeing the proper
chirality, it has a pivotal role in proper positioning of P-site
substrates [34–38], a prerequisite for the formation of func-
tional ribosomes. It may also inﬂuence, in a still unknown
mechanism, the entrance of the newly formed peptides to the
protein exit tunnel. Inherent conformational mobility enabling
discrimination during selected steps of protein biosynthesis, as
suggested for the nucleotide U2585, has been identiﬁed also in
the ribosomal exit tunnel. Thus, under conditions unfavorable
for the maturation of a nascent protein, speciﬁc sequences,
associated with elongation arrest, appear to cause the tip
of the b-hairpin of protein L22 to swing across the tunnel
[12].
The protein exit tunnel is the preferred target of anti-mi-
crobial drugs from the macrolide and ketolides families, and
crystallographic studies, using D50S as a pathogen model
demonstrated unambiguously that clinically relevant amounts
of these antibiotics block the tunnel and interfere with nascentchain progression (Fig. 3(b)) [7,12–15,39]. Streptogramins are
unique among the ribosome-targeting antibiotics, since they
consist of two components (A and B) that act synergistically
[40] converting weak bacteriostatic eﬀects into lethal bacteri-
cidal activity. Each compound has a moderate bacteriostatic
activity, but their combination is quite powerful, displaying a
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persisting after drug removal [43,44]. Among them is Syner-
cid, a recently approved injectable streptogramin with ex-
cellent activity against gram-positive bacteria [45], which is
composed of 30:70 combination of dalfopristin (SA) and
quinupristin (SB),
The crystal structure of D50S complex, with clinically rele-
vant concentrations of Synercid, showed that quinupristin
binds to the exit tunnel [15] to the crevice favored by the
common macrolides. Its binding mode is, similar, albeit not
identical, to those of common macrolides [7]. Nevertheless,
despite its slight inclination towards the tunnel wall (Fig. 3(d)),
which rationalizes its reduced antibacterial eﬀects in the ab-
sence of its SA mate, it is involved in most of the macrolide-
typical interactions of its desosamine sugar with A2058 and its
vicinity [15]. This binding mode is in accord with the compe-
tition between erythromycin and SB compounds [46] and with
the common resistance mechanisms to both classes of antibi-
otics, namely methylation or mutation of A2058 (reviewed in
[39,47]). The interactions of the SB component of Synercid

with A2058 shed light on the absence of signiﬁcant binding of
SB to the large ribosomal subunit from the Archaeon H.
marismortui [9], as this species possesses the typical eukaryotic
G in position 2058, rather than the common eubacterial A.
The second Synercid component, dalfopristin, binds to the
PTC by a network of hydrophobic interactions in a position
almost overlapping chloramphenicol binding site [7], consis-
tent with SA interference with substrate binding, reported two
decades ago [48]. However, contrary to chloramphenicol,
dalfopristin binding induces remarkable alterations in the PTC
[15], consistent with conclusions based on biochemical data
[49,50]. The most signiﬁcant dalfopristin induced conforma-
tional change, caused by space exclusion, is a 180 ﬂip of the
base of nucleotide U2585 (Figs. 3(b) and (c)), one of the an-
chors of the rotatory motion. In the native structure, this base
points into the PTC, at the exit tunnel entrance. In its ﬂipped
orientation U2585 interacts with C2606 and G2588, leading to
a fairly stable alteration of the P-region of the PTC, reasoning
its severe eﬀect on P-site tRNA proper positioning [40]. In-
terestingly, though the inversion of U2585 orientation appears
to be crucial for SA binding, U2585 conformation is hardly
changed in H50S-streptogramin complex [51]. This ﬁnding
correlates well with the inherent diﬀerences in PTC confor-
mations in H50S [5] and in eubacterial ribosomes [3,4], and
accords with the suggestion that chloramphenicol and strep-
togramins exploit diﬀerent inhibitory mechanisms on archea
compared to eubacteria [49].
Despite the relative stability of U2585 ﬂipped orientation in
the presence of dalfopristin, it is conceivable that its natural
interactions with the PTC and the tRNA-30ends could compete
with those provided in the ﬂipped orientation. This competi-
tion should cause ejection or re-localization of the drug, jus-
tifying the reduced antibacterial activity observed for binding
dalfopristin by itself, as well as the need for additional con-
tributions in order to achieve signiﬁcant antibacterial activity
(Fig. 3(c)). Quinupristin binding could supply this need, since
it should block the relocation or the ejection of dalfopristin,
thus ﬁxing U2585 in its ﬂipped orientation while eliminating
nascent peptides progression. Importantly, in the structure of
its complex with D50S both Synercid components interact
with each other and share contacts with nucleotide A2062 [15],
consistent with observations made in solution [50,52]. It ap-pears, therefore, that conﬁning U2585 to its ﬂipped confor-
mation, by itself or as a consequence of the interactions
between the two Synercid components via the shared con-
tacts with A2062, is the main contributor to Synercid syn-
ergetic eﬀect in bactericidal activity as well as for its prolonged
activity.
Dual drug binding leading to enhanced activity was ob-
served also in D50S complex with azithromycin [14], a 15-
members macrolides developed to combat resistance [53].
Similar to all macrolides studied so far, azithromycin exerts its
antimicrobial activity by blocking the exit tunnel. Contrary to
the others, two azithromycin molecules, interacting with each
other, bind simultaneously to the ribosome (Fig. 3(e)). Be-
tween the two bound molecules, one is located in a position
and orientation similar to that observed for erythromycin [7],
and the second reaches the other side of the tunnel, where it
interacts with ribosomal proteins L4 and L22, both implied in
macrolide resistance [54]. The two azithromycin molecules are
in direct contact, and crystallographic criteria indicate a
stronger binding of the second [14]. This mode of binding was
originally thought to be speciﬁc for D. radiodurans, since one
of the contacts of the second azithromycin involves a non-
conserved glycine (gly60) of protein L4 [7]. However, since
azithromycin interacts with the backbone of gly60, and since
computer simulations showed that various side-chains could
be accommodated in a way that would not perturb these in-
teractions, it is likely that two azithromycin molecules can bind
simultaneously only to D. radiodurans. Likewise, the second
azithromycin, which is located in proximity to protein L22 b-
hairpin tip, could induce a swing of the b-hairpin across the
tunnel, similar to the action of troleandomycin [12].
Further analysis of azithromycin binding mode, including
modeling and energetic considerations accompanied with new
ﬁndings showing dual and triple binding for several members
of the macrolide–ketolide family (data not shown), indicated
rather high probability for similar binding modes in various
ribosomes, including those of pathogenic bacteria. Our studies
show that species likely to bind simultaneously two azithro-
mycin molecules include Haemophilus inﬂuenzae, E. coli,
Mycobacterium tuberculosis, Helicobacter pylori, Mycoplasma
pneumoniae and Mycobacterium leprae (A. Sittner and
A. Bashan, to be published).5. Conclusions
We have shown that the ribosomal elaborate architecture is
designed for navigating and controlling peptide-bond forma-
tion and continuous amino-acid polymerization, thus con-
ﬁrming that the ribosome contributes positional, rather than
chemical catalysis. Our conclusions are based on the linkage
between internal ribosomal symmetrical framework and the
orientation of the tRNA substrates, as well as on the revelation
of a ribosomal pattern outlining the exact path taken by
tRNA-30end during A- to P-site passage.
Our analysis of the spectacular ribosomal architecture ra-
tionalizes several seemingly contradictory ﬁndings: (a) a siz-
able symmetry related region within the giant asymmetrical
ribosome, which could be rationalized by the requirement for
mutual substrate stereochemistry suitable for the formation of
the peptide bond; (b) PTC mobility and tolerance vs. the exact
localization of the ribosomal substrates, found to be manda-
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substrate precise orientation explains the location of the PTC
at the bottom of a deep cavity, as the upper rim of this cavity
provides the remote interactions that govern substrate’s
placement; (c) single peptide bond formation by protein-free
23S RNA vs. the signiﬁcant contribution of protein L2 to ef-
ﬁcient amino acid polymerization. Thus, apart from providing
the structural basis for L2 evolutionary conservation, these
ﬁndings emphasize the dual missions of ribosomal catalysis:
peptide bond formation and amino acid polymerization.
Finally, we identiﬁed two universally conserved multi-func-
tional PTC nucleotides that do not obey the ribosomal twofold
symmetry and possess incredible dynamics, enabling their
participation in peptide bond formation. One of them, A2602,
is suggested to facilitate PTC-substrate conformational rear-
rangements, and propel the A-site tRNA-30end rotatory mo-
tion. The second, U2585, is anchoring this motion, and seems
to be involved in tunneling nascent proteins into their exit
tunnel as well as in D-amino acids discrimination. U2585 plays
also a key role in acquiring the synergetic enhancement of the
two Synercid components. Thus, upon the binding of Syn-
ercid streptograminA component, U2585 ﬂips out of the PTC
into a non-productive orientation, which becomes almost
completely irreversible upon the binding of the streptograminB
component of Synercid. Extending our studies on synergistic
eﬀects originating from interactions between two antibiotic
compounds, we propose that enhanced antibiotic eﬀect could
be correlated with the dual binding of the same antibiotic
compound. Thus, the improved antimicrobial properties of
azithromycin, which were originally attributed to the spe-
ciﬁc properties of D. radiodurans, could be extended, by
careful simulation, to many other species, including patho-
genic bacteria.
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